中南建設(000961.SZ):上半年新增借款75.65億元
格隆匯 8 月 24日丨中南建設(000961.SZ)公佈,截至2020年6月30日,公司合併報表範圍內各項借款餘額(含應付利息)781.42億元,較2019年末借款餘額(含應付利息)705.77億元增加75.65億元,佔2019年末經審計淨資產268.23億元的28.20%。
新增借款均屬公司正常經營需要,2020年上半年公司新增借款75.65億元,僅佔2020年6月30日公司全部負債的2.62%,不會對公司經營和償債能力產生不利影響。增加以上借款後,2020年6月末公司各項借款餘額781.42億元,仍在行業類似經營規模的公司裏處於較低水平。公司負債規模小,償債能力強,實際經營風險低。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.